{"id":"interruption-of-glivec","safety":{"commonSideEffects":[{"rate":"20-50%","effect":"Myelosuppression"},{"rate":"10-30%","effect":"Nausea"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"5-20%","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL3770173","moleculeType":"Small molecule","molecularWeight":"440.32"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by binding to the ATP-binding site of these kinases, thereby inhibiting their activity and preventing the proliferation of cancer cells. This leads to a reduction in tumor size and an improvement in symptoms.","oneSentence":"Glivec is a tyrosine kinase inhibitor that targets BCR-ABL, c-KIT, and PDGFR.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:16:35.778Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic myeloid leukemia"},{"name":"Acute lymphoblastic leukemia"}]},"trialDetails":[{"nctId":"NCT00367861","phase":"PHASE3","title":"Prospective Multicentric Randomized Study of Glivec® in Advanced GIST Expressing C-kit: Interruption After 5 Years vs Maintenance","status":"COMPLETED","sponsor":"Centre Leon Berard","startDate":"2002-05","conditions":"Sarcoma, Gastro-intestinal Stromal Tumors (GIST)","enrollment":564}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"interruption of Glivec®","genericName":"interruption of Glivec®","companyName":"Centre Leon Berard","companyId":"centre-leon-berard","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Glivec is a tyrosine kinase inhibitor that targets BCR-ABL, c-KIT, and PDGFR. Used for Chronic myeloid leukemia, Acute lymphoblastic leukemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}